文献速递心力衰竭与心肌病

HFA-ICOS评分在蒽环类药物心血管毒性中的验证

Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
PubMed 文献 · Eur Heart J · 2025-01-01

本研究基于CARDIOTOX注册研究(NCT02039622)中1066例接受蒽环类药物治疗的患者,按HFA-ICOS评分进行风险分层,旨在验证该评分对蒽环类药物所致心血管毒性的预测能力。主要终点为症状性或中重度无症状性癌症治疗相关心功能障碍(CTRCD)。结果显示,随着HFA-ICOS评分升高,症状性或中重度无症状CTRCD及全因死亡率显著增加,模型在12个月预测中表现出良好的校准度和区分度。

要点

  • HFA-ICOS评分可有效对蒽环类治疗患者进行心血管毒性风险分层。
  • 极高危患者发生症状性或中重度无症状CTRCD及全因死亡的风险显著增高。
  • 该评分对12个月症状性或中重度无症状CTRCD预测的AUC为0.78。

核心结论

  • HFA-ICOS评分能有效对患者心血管毒性风险进行分类,并对高危蒽环类相关心血管毒性及全因死亡展现出较强预测能力。

研究设计与样本

  • 基于CARDIOTOX注册研究(NCT02039622)的验证性分析,纳入1066例接受蒽环类药物治疗的患者,按HFA-ICOS评分进行风险分层。

主要发现

  • 中位随访54.8个月(四分位距24.6-81.8),197例(18.4%)死亡,718例(67.3%)发生CTRCD(症状性45例,中重度无症状24例,轻度无症状649例)。
  • 按HFA-ICOS标准,低危571例(53.6%)、中危333例(31.2%)、高危152例(14.3%)、极高危10例(0.9%)。
  • 模型对12个月症状性或中重度无症状CTRCD预测校准良好(Brier评分0.04,95%CI 0.03-0.05),区分度良好(AUC 0.78,95%CI 0.70-0.82;Uno C统计量0.78,95%CI 0.71-0.84)。

临床怎么用

  • 在蒽环类药物治疗前,可采用HFA-ICOS评分对患者进行基线心血管毒性风险分层,识别高危和极高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Baseline cardiovascular toxicity risk stratification is critical in cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology Society (ICOS) score aims to assess this risk but lacks real-life validation. This study validates the HFA-ICOS score for anthracycline-induced cardiovascular toxicity. METHODS: Anthracycline-treated patients in the CARDIOTOX registry (NCT02039622) were stratified by the HFA-ICOS score. The primary endpoint was symptomatic or moderate to severe asymptomatic cancer therapy-related cardiac dysfunction (CTRCD), with all-cause mortality and cardiovascular mortality as secondary endpoints. RESULTS: The analysis included 1066 patients (mean age 54 ± 14 years; 81.9% women; 24.5% ≥65 years). According to the HFA-ICOS criteria, 571 patients (53.6%) were classified as low risk, 333 (31.2%) as moderate risk, 152 (14.3%) as high risk, and 10 (0.9%) as very high risk. Median follow-up was 54.8 months (interquartile range 24.6-81.8). A total of 197 patients (18.4%) died, and 718 (67.3%) developed CTRCD (symptomatic: n = 45; moderate to severe asymptomatic: n = 24; and mild asymptomatic: n = 649). Incidence rates of symptomatic or moderate to severe symptomatic CTRCD and all-cause mortality significantly increased with HFA-ICOS score [hazard ratio 28.74, 95% confidence interval (CI) 9.33-88.5; P < .001, and hazard ratio 7.43, 95% CI 3.21-17.2; P < .001) for very high-risk patients. The predictive model demonstrated good calibration (Brier score 0.04, 95% CI 0.03-0.05) and discrimination (area under the curve 0.78, 95% CI 0.70-0.82; Uno's C-statistic 0.78, 95% CI 0.71-0.84) for predicting symptomatic or severe/moderate asymptomatic CTRCD at 12 months. CONCLUSIONS: The HFA-ICOS score effectively categorizes patients by cardiovascular toxicity risk and demonstrates strong predictive ability for high-risk anthracycline-related cardiovascular toxicity and all-cause mortality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Rivero-Santana, Saldaña-García, Caro-Codón, et al. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2025. PMID: 39106857. doi:10.1093/eurheartj/ehae496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。